ANIK (Anika Therapeutics) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANIK Anika Therapeutics Inc ANIK
64 GF Score
Price $15.04
GF Value $20.67
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics FFO per Share?

FFO per Share only applies to REITs.

ANIK
64GF Score
Anika Therapeutics Inc ANIK
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Anika Therapeutics (ANIK) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued. The current stock price of $15.04 is trading 27.3% below its estimated GF Value™ of $20.67. GuruFocus considers Anika Therapeutics to be Modestly Undervalued.

Key valuation signals for ANIK:

  • FFO per Share:
  • GF Value™: $20.67 vs. price of $15.04 (27.3% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anika Therapeutics Business Description

Other Exchanges AKP:Germany
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
64GF Score

Get the complete analysis for ANIK

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.04
Price
$20.67
GF Value